Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).

被引：1

作者：

Smit, Marie-Anne Damiette

Borghaei, Hossein

Owonikoko, Taofeek Kunle

Hummel, Horst-Dieter

Johnson, Melissa Lynne

Champiat, Stephane

Salgia, Ravi

Udagawa, Hibiki

Boyer, Michael J.

Govindan, Ramaswamy

机构：

[1] Amgen Inc, Translat Med, Thousand Oaks, CA 91320 USA

[2] Fox Chase Canc Ctr, Dept Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[3] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA

[4] Univ Hosp Wurzburg, Translat Oncol Early Clin Trial Unit ECTU, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany

[5] Tennessee Oncol, Lung Canc Res, Sarah Cannon Res Inst, Nashville, TN USA

[6] Gustave Roussy, Inst Cancerol, Villejuif, France

[7] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[9] Chris OBrien Lifehouse, Camperdown, NSW, Australia

[10] Washington Univ, Sch Med, Div Hematol, St Louis, MO USA

[11] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8577

引用

页数：1

共 50 条

[1] Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
Owonikoko, Taofeek Kunle
Borghaei, Hossein
Champiat, Stephane
Paz-Ares, Luis G.
Govindan, Ramaswamy
Boyer, Michael J.
Johnson, Melissa Lynne
Udagawa, Hibiki
Hummel, Horst-Dieter
Salgia, Ravi
Blackhall, Fiona Helen
Boosman, Rene J.
Lai, Wei-Chu Victoria
Dowlati, Afshin
Vokes, Everett E.
Hann, Christine L.
Chiang, Anne C.
Endraca, Marichu
Soman, Neelesh
Smit, Marie-Anne Damiette
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[2] A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC
Owonikoko, T.
Boyer, M.
Johnson, M.
Govindan, R.
Rodrigues, L.
Blackhall, F.
Boosman, R.
Champiat, S.
Hummel, H.
Lai, W. V.
Udagawa, H.
Chiang, A.
Dowlati, A.
Hann, C.
Salgia, R.
Vokes, E.
Minocha, M.
Sadraei, N.
Shetty, A.
Smit, M.
Zhang, Y.
Sable, B.
Pati, A.
Roy, S.
Borghaei, H.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S126 - S126
[3] AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
Cooke, K.
Estrada, J.
Zhan, J.
Werner, J.
Bailis, J.
Hughes, P.
Shetty, A.
Canon, J.
Smit, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S343 - S344
[4] AMG 757, A HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNE THERAPY AGAINST DLL3 IN SCLC: PHASE 1 INTERIM RESULTS
Borghaei, Hossein
Boyer, Michael
Johnson, Melissa
Govindan, Ramaswamy
Rodrigues, Luis Paz-Ares
Blackhall, Fiona
Boosman, Rene
Champiat, Stephane
Hummel, Horst-Dieter
Lai, W. Victoria
Udagawa, Hibiki
Chiang, Anne
Dowlati, Afshin
Hann, Christine
Salgia, Ravi
Vokes, Everett
Minocha, Mukul
Hashemi-Sadraei, Nooshin
Shetty, Aditya
Smit, Marie-Anne Damiette
Yang, Hui
Owonikoko, Taofeek
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A219 - A220
[5] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
Paz-Ares, L.
Owonikoko, T. K.
Johnson, M.
Govindan, R.
Izumi, H.
Lai, V.
Borghaei, H.
Boyer, M.
Boosman, R. J.
Hummel, H-D.
Blackhall, F.
Dowlati, A.
Zhang, Y.
Mukherjee, S.
Sable, B.
Pati, A.
Shetty, A.
Sadraei, N. Hashemi
Champiat, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721
[6] Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE®) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC)
Cooke, Keegan
Estrada, Juan
Zhan, Jinghui
Werner, Jonathan
Caenepeel, Sean
Giffin, Mike
Bailis, Julie M.
Coxon, Angela
Hughes, Paul E.
Canon, Jude
CANCER RESEARCH, 2020, 80 (16)
[7] Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
Owonikoko, Taofeek K.
Champiat, Stephane
Johnson, Melissa Lynne
Govindan, Ramaswamy
Izumi, Hiroki
Lai, W. Victoria Victoria
Borghaei, Hossein
Boyer, Michael J.
Boosman, Rene J.
Hummel, Horst-Dieter
Blackhall, Fiona Helen
Reguart, Noemi
Dowlati, Afshin
Zhang, Yiran
Mukherjee, Sujoy
Minocha, Mukul
Zhou, Yanchen
Shetty, Aditya
Sadraei, Nooshin Hashemi
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[8] Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC
Giffin, M.
Cooke, K.
Lobenhofer, E.
Friedrich, M.
Raum, T.
Coxon, A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S971 - S971
[9] Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
Ramalingam, S. S.
Ahn, M-J.
Akamatsu, H.
Blackhall, F.
Borghaei, H.
Hummel, H-D.
Johnson, M.
Reck, M.
Zhang, Y.
Jandial, D.
Cheng, S.
Paz-Ares, L.
ANNALS OF ONCOLOGY, 2022, 33 : S103 - S104
[10] Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
Dowlati, A.
Byers, L. A.
Johnson, M. L.
Aljumaily, R.
Prenen, H.
Zhang, A.
Minocha, M.
Shetty, A.
Sadraei, N. Hashemi
ANNALS OF ONCOLOGY, 2021, 32 : S1172 - S1173

← 1 2 3 4 5 →